Rohan R M, Ricciarelli E, Kiefer M C, Resnick C E, Adashi E Y
Department of Obstetrics/Gynecology and Physiology, University of Maryland School of Medicine, Baltimore 21201.
Endocrinology. 1993 Jun;132(6):2507-12. doi: 10.1210/endo.132.6.7684977.
Most but not all of the established insulin-like growth factor-binding proteins (IGFBPs) are expressed in the rat ovary. To continue the process of characterizing these ovarian IGFBPs, a solution hybridization/RNase protection assay was used to study IGFBP-6 gene expression, cellular localization, and hormonal regulation in the immature rat ovary. Total RNA was hybridized with a 458-base long 32P-labeled rat IGFBP-6 cRNA. A single protected fragment (380 bases long) corresponding to IGFBP-6 transcripts was identified in RNA from ovary and lung, but not kidney or liver. The amount of IGFBP-6 transcripts was higher in ovaries from immature rats (25-28 days old) than in ovaries from adult rats and was higher in theca-interstitial than in granulosa cell preparations. Hypophysectomy resulted in a significant (P < 0.05) 2.3 +/- 0.7-fold (mean +/- SD) increase in whole ovarian IGFBP-6 transcripts. This suggests that ovarian IGFBP-6 gene expression is subject to inhibition by one or more pituitary hormones. Therefore, the effect of replacement of FSH, GH, diethylstilbestrol (DES), or combinations thereof was evaluated. Treatment with FSH resulted in a 2.4-fold decrease (P < 0.05) in the abundance of ovarian IGFBP-6 transcripts relative to that in hypophysectomized controls. Provision of DES yielded comparable results. Moreover, the combined provision of FSH and DES resulted in a synergistic decrease (6.0-fold) in ovarian IGFBP-6 transcripts. In contrast, treatment of hypophysectomized rats with GH proved without effect. However, treatment with FSH or DES in addition to GH resulted in a decrease in ovarian IGFBP-6 transcripts (3.9- and 2.7-fold, respectively). To assess the role of ovarian IGFBP-6, its influence on gonadotropin action in primary cultures of rat granulosa cells was also studied. Increasing concentrations (0.01-1 micrograms/ml) of recombinantly expressed human IGFBP-6 did not inhibit the FSH-supported accumulation of either progesterone or estradiol. These findings 1) establish the theca-interstitial compartment of the immature rat ovary as a prominent site of IGFBP-6 gene expression, 2) implicate FSH and DES as inhibitors of IGFBP-6 transcript levels in the whole ovary, 3) and disclose the limited antigonadotropic action of IGBP-6F on the rat granulosa cell.
大多数(但并非全部)已确定的胰岛素样生长因子结合蛋白(IGFBPs)在大鼠卵巢中表达。为了继续对这些卵巢IGFBPs进行特性描述,采用溶液杂交/核糖核酸酶保护分析法研究未成熟大鼠卵巢中IGFBP-6基因的表达、细胞定位及激素调节。将总RNA与一段458个碱基长的32P标记的大鼠IGFBP-6互补RNA杂交。在卵巢和肺的RNA中鉴定出一个与IGFBP-6转录本相对应的单一受保护片段(380个碱基长),而在肾或肝的RNA中未鉴定出。未成熟大鼠(25 - 28日龄)卵巢中IGFBP-6转录本的量高于成年大鼠卵巢,且在卵泡膜-间质细胞制剂中的量高于颗粒细胞制剂。垂体切除导致整个卵巢IGFBP-6转录本显著(P < 0.05)增加2.3 ± 0.7倍(平均值 ± 标准差)。这表明卵巢IGFBP-6基因表达受到一种或多种垂体激素的抑制。因此,评估了促卵泡激素(FSH)、生长激素(GH)、己烯雌酚(DES)或其组合替代治疗的效果。用FSH治疗导致卵巢IGFBP-6转录本丰度相对于垂体切除对照降低2.4倍(P < 0.05)。给予DES产生了类似的结果。此外,联合给予FSH和DES导致卵巢IGFBP-6转录本协同降低(6.0倍)。相反,用GH治疗垂体切除的大鼠未产生效果。然而,除GH外再用FSH或DES治疗导致卵巢IGFBP-6转录本降低(分别为3.9倍和2.7倍)。为了评估卵巢IGFBP-6的作用,还研究了其对大鼠颗粒细胞原代培养中促性腺激素作用的影响。重组表达的人IGFBP-6浓度增加(0.01 - 1微克/毫升)并未抑制FSH支持的孕酮或雌二醇的积累。这些发现1)确定未成熟大鼠卵巢的卵泡膜-间质区是IGFBP-6基因表达的主要部位,2)表明FSH和DES是整个卵巢中IGFBP-6转录本水平的抑制剂,3)并揭示了IGBP-6F对大鼠颗粒细胞的有限抗促性腺激素作用。